PMID- 33781065
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1840-2879 (Electronic)
IS  - 1840-1848 (Linking)
VI  - 49
IP  - 3
DP  - 2020 Dec
TI  - Stereotactic Body Radiation Therapy (SBRT) for Liver Oligometastases: Outcomes 
      and Safety.
PG  - 225-231
LID - 10.5644/ama2006-124.311 [doi]
AB  - OBJECTIVE: The aim of this study was to investigate adverse effects, progression 
      free survival (PFS), one-year local control (LC) and one-year overall survival 
      (OS) of patients with liver oligometastases treated with stereotactic body 
      radiotherapy (SBRT), and whether there was a significant difference in these 
      parameters in patients with primary colorectal cancer compared to other tumor 
      localizations. PATIENTS AND METHODS: Patients were simulated using 
      four-dimensional computed tomography (4DCT). Using volumetric modulated arc 
      therapy (VMAT) technique, SBRT was performed on 16 patients with <3 liver 
      metastases. The prescribed dose was 60 Gy in 8 fractions (BED 105 Gy). Cone beam 
      CT (CBCT) was used for image guidance before each fraction with online 
      correction. RESULTS: There were no adverse effects. Median PFS for all patients, 
      patients with primary colorectal cancer, and patients with primary non-colorectal 
      cancer was 11 months (SE 2.1), 16 months (SE 2.8), 6 months (SE 2.4), 
      respectively. There was no significant difference in the PFS for these two 
      observed groups (P=0.09). The one-year LC was 62.5%. Patients with primary 
      colorectal cancer had one-year LC of 87.5%, while the group of patients with 
      primary non-colorectal cancer had one-year LC of 37.5% (P=0.063). The total 
      one-year OS was 87.5%. In the group of patients with primary colorectal cancer, 
      the one-year OS was 100%, while in the group of patients with primary 
      non-colorectal cancer, the one-year OS was 75% (P=0.317). CONCLUSION: SBRT with 8 
      x 7.5 Gy can be safely delivered and is effective method of treating liver 
      oligometastases.
CI  - Copyright (c) 2020 by Academy of Sciences and Arts of Bosnia and Herzegovina.
FAU - Cazic, Dejan
AU  - Cazic D
AD  - International Medical Centers Banja Luka, Affidea, Center for Radiotherapy, Banja 
      Luka, Bosnia and Herzegovina. dejan.cazic@affidea.com.
FAU - Marosevic, Goran
AU  - Marosevic G
AD  - International Medical Centers Banja Luka, Affidea, Center for Radiotherapy, Banja 
      Luka, Bosnia and Herzegovina; Medical Faculty, University of Banja Luka, Banja 
      Luka, Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
PL  - Bosnia and Herzegovina
TA  - Acta Med Acad
JT  - Acta medica academica
JID - 101587903
SB  - IM
MH  - Humans
MH  - *Liver Neoplasms/radiotherapy
MH  - *Radiosurgery/adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Liver
OT  - Oligometastases
OT  - SBRT
EDAT- 2021/03/31 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/03/30 05:44
PHST- 2020/07/13 00:00 [received]
PHST- 2020/12/30 00:00 [accepted]
PHST- 2021/03/30 05:44 [entrez]
PHST- 2021/03/31 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - ama2006-124.311 [pii]
AID - 10.5644/ama2006-124.311 [doi]
PST - ppublish
SO  - Acta Med Acad. 2020 Dec;49(3):225-231. doi: 10.5644/ama2006-124.311.